Microglia in Epilepsy: From Molecular Mechanism to Therapeutic Strategy
Cells · 02.05.2026 · 15 (9) · 835
DOI: 10.3390/cells15090835 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 02.05.2026. Verfasst von Yam Nath Paudel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, School of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA. Hauptthemen laut MEDLINE: Microglia, Epilepsy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Countermeasures Against Chemical Threats (CounterACT) Program, the National Institutes of Health (NIH) Office of the Director, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
The limit of disease-modifying therapeutic strategies against epilepsy has prompted mainstream epilepsy research toward understanding the pathways contributing to epileptic seizures. Microglia, the powerhouse of the brain’s innate immune system, is known for its role in epileptic seizures, contributing via neuroinflammation, neuronal death, and neurogenesis. Therapeutic targeting of microglia with its inhibitor and therapeutic compounds modulating its activation reduces the development of spontaneous recurrent seizure after status epilepticus in a pre-clinical model. Herein, we review various aspects of microglia in epilepsy, including their contribution to seizure-induced neuronal death and neurogenesis, the outcome of depleting microglia (both pharmacologically and genetically), the aspects of microglia–astrocyte interaction, and promising therapeutic outcomes achieved by targeting microglia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, School of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
- 1st Department of Neurology, Eginition Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.
- Department of Pharmacotherapy and Outcomes Sciences, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA.
- Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
ORCID-Profile: Efthalia Angelopoulou, Sai Kulkarni, Laxmikant S Deshpande
Förderung
- NINDS NIH HHS
- Countermeasures Against Chemical Threats (CounterACT) Program, the National Institutes of Health (NIH) Office of the Director
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Paudel, Y. N., Angelopoulou, E., Kulkarni, S., Blair, R. E., & Deshpande, L. S. (2026). Microglia in Epilepsy: From Molecular Mechanism to Therapeutic Strategy. Cells, 15(9), 835. https://doi.org/10.3390/cells15090835
Vancouver
Paudel YN, Angelopoulou E, Kulkarni S, Blair RE, Deshpande LS. Microglia in Epilepsy: From Molecular Mechanism to Therapeutic Strategy. Cells. 2026;15(9):835. doi:10.3390/cells15090835
BibTeX
@article{Paudel2026,
author = {Paudel, Yam Nath and Angelopoulou, Efthalia and Kulkarni, Sai and Blair, Robert E and Deshpande, Laxmikant S},
title = {Microglia in Epilepsy: From Molecular Mechanism to Therapeutic Strategy},
journal = {Cells},
year = {2026},
volume = {15},
number = {9},
pages = {835},
doi = {10.3390/cells15090835}
}
EUVIMED